Experimental MS drug tested in kids, but study halted early

NCT ID NCT03368664

Terminated Disease control Sponsor: Genzyme, a Sanofi Company Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 05, 2026 · Updated 4 times

Summary

This study tested the drug alemtuzumab in children aged 10 to 18 with relapsing-remitting multiple sclerosis (MS) whose disease was still active despite other treatments. The goal was to see if the drug could reduce new brain lesions and improve quality of life. However, the trial was terminated early after enrolling only 16 participants, so the findings are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Alemtuzumab (also known as Lemtrada)
What this could lead to: If successful, this could provide a treatment option for children with active MS who have not responded to other therapies.
What could go wrong: The trial was terminated early with only 16 participants, so results are limited. Alemtuzumab also carries risks of serious autoimmune reactions and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

Investigational Site Number : 2500001

Le Kremlin-Bicêtre, 94270, France
Investigational Site Number : 2500002

Strasbourg, 67000, France
Investigational Site Number : 3800004

Naples, Napoli, 80131, Italy
Investigational Site Number : 3800005

Cagliari, 09126, Italy
Investigational Site Number : 6160002

Poznan, Greater Poland Voivodeship, 60-780, Poland
Investigational Site Number : 6160003

Lodz, Lódzkie, 93-338, Poland
Investigational Site Number : 6430001

Moscow, 119602, Russia
Investigational Site Number : 6430002

Saint Petersburg, 197110, Russia
Investigational Site Number : 6430004

Moscow, 129110, Russia
Investigational Site Number : 6430005

Saint Petersburg, 197022, Russia
Investigational Site Number : 7920001

Ankara, 06560, Turkey (Türkiye)
Investigational Site Number : 7920003

Istanbul, 34093, Turkey (Türkiye)
Investigational Site Number : 8260002

London, London, City of, WC1N 3JH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.